Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

A Bioorthogonally Cleavable N-Oxide Linker for Prodrug Design: Elucidating the Structure-Cyclization Kinetics Relationships for Controlled Drug Release.

Created on 06 Jul 2026

Authors

Qingyan Zhao, Yiyao Pan, Guofeng Jiao, Weilin He, Xia Lv, Mingquan Xiong, Xiaoguang Bao, Huabing Chen, Hengte Ke, Xingyue Ji

Published in

Journal of medicinal chemistry. Jul 05, 2026. Epub Jul 05, 2026.

Abstract

Bioorthogonal bond cleavage reactions that exhibit rapid kinetics in both the initial click and subsequent release steps are essential for in vivo applications. In this study, we focus on the bioorthogonal decaging reaction between an N-oxide and silylborane, and systematically modify the structure of an N-oxide-masked ethylenediamine linker, which undergoes cyclization to release the attached payload upon silylborane activation. Our results uncovered significant structure-cyclization kinetics relationships, leading to the identification of several novel linkers that combine favorable stability with rapid cyclization kinetics (T1/2 on the scale of minutes) following activation. Using one representative linker, we constructed a bioorthogonal prodrug of CA-4 that displayed potent antitumor activity only in combination with silylborane both in vitro and in vivo. We anticipate that these ethylenediamine linkers will have potential application in the design of prodrugs.

PMID:
42402214
Bibliographic data and abstract were imported from PubMed on 06 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 15
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement